ISRCTN71924789已完成Unknown
utraceutical-based therapy in the management of temporomandibular disorders
试验速览
- 阶段
- Unknown
- 状态
- 已完成
- 入组人数
- 193
研究概览
简要总结
2024 Results article in https://pubmed.ncbi.nlm.nih.gov/38958698/ (added 08/07/2024)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Presence of dysfunctions of the craniocervical musculature, in the presence or absence of parafunction
- •2. Presence of muscular pain at the level of the masseter of the medium-high entity with a minimum value of 40 and a maximum of 100 according to the VNS (verbal numerical scale), spontaneous and/or investigated by palpatory manoeuvres
- •3. Presence of arthralgia in at least one temporomandibular joint
- •4. Presence of the following comorbidities such as headache attributed to temporomandibular disorders, cervicalgia
- •5. Presence of sleep disturbances (no OSAS) and emotional factors (stress and anxiety) investigated with a nominal scale (presence or absence)
- •6. Patients waiting for or undergoing conservative gnathological therapy
排除标准
- •1. Psychiatric pathologies
- •2. Systemic pathologies with disease-related muscular impairment
- •3. Pain therapy or myorelaxant medication
研究者
相似试验
进行中（未招募）
不适用
METRONOMIC CHEMOTHERAPY WITH URACIL/TEGAFUR (UFT), CYCLOPHOSPHAMIDE (CTX) AND CELECOXIB IN PRETREATED PATIENTS WITH ADVANCED GASTROINTESTINAL MALIGNANCIES: A PILOT CLINICAL STUDY WITH PHARMACOKINETIC AND PHARMACODYNAMIC EVALUATIONS - COMET-GIEUCTR2007-000065-38-ITAZIENDA USL 6 LIVORNO ZONA LIVORNESE
已完成
3 期
Study of Teduglutide Effectiveness in Parenteral Nutrition (PN)-Dependent Short Bowel Syndrome (SBS) SubjectsShort Bowel SyndromeNCT00798967Shire86
进行中（未招募）
不适用
SURECAN: Survivors rehabilitation evaluation after cancerISRCTN67900293Queen Mary University of London344
已完成
2 期
Best available therapy versus JAK Inhibition in patients with high risk polycythaemia vera or essential thrombocythaemia who are resistant or intolerant to hydroxycarbamideCancerISRCTN61925716niversity of Birmingham (UK)306
进行中（未招募）
1 期
An open-label phase Ib time-to-event continual reassessment method of dose-escalation of tolinapant (ASTX660) in combination with standard radical chemotherapy and radiotherapy in patients with cervical cancerAdenocarcinoma or squamous cell carcinoma of the cervixCancerISRCTN18574865niversity of Southampton42